Mnkd stock price movements have been closely tied to

mnkd stock price movements have been closely tied to FDA updates in recent sessions. Investors are watching whether regulatory clarity on inhaled insulin expands market adoption, which could shift valuation multiples upward. MannKind Corporation (NASDAQ: MNKD ) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts . On June 19, analyst Faisal Khurshid of Leerink Partners reiterated a Buy rating on MannKind Corporation (NASDAQ:MNKD), reducing the price target to $7 from $9. Despite some near-term uncertainties, the analyst based the rating on the company’s long-term growth, stating that the stock is currently undervalued. We have seen 96 institutional investors add shares of $MNKD stock to their portfolio, and 143 decrease their positions in their most recent quarter. Market sentiment leans bullish if Q2 revenue beats consensus; otherwise, biotech macro headwinds could pressure the stock toward $4.00 support.